Tatiana L. Vershinina
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Tatiana L. Vershinina has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Elena S. Vasichkina
Almazov National Medical Research Center
9 shared publications - Anna A. Kostareva
Almazov National Medical Research Centre
7 shared publications - Tatiana M. Pervunina
Almazov National Medical Research Centre
6 shared publications - Yu. V. Fomicheva
Almazov National Medical Research Center
5 shared publications - Artem Kiselev
Institute for Quantitative Health Science and Engineering (IQ), Michigan State University, East Lansing, MI, USA
3 shared publications - O. V. Melnik
Almazov National Medical Research Center
3 shared publications
Latest Publications
- Open Access
- 23 January 2026
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 24 (11) , 4567
Potential and prospects for using biomedical resource collections obtained from pediatric patients for clinics and research
Aim . To demonstrate the development and potential applications of biomedical resource collections of pediatric patient biomaterials, as well as the potential for their differentiated use for clinical and research purposes in a multidisciplinary hospital setting at a federal research center. Material and methods . The study included biomaterial from pediatric patients and their first-degree relatives, banked between 2016 and 2025 as part of research projects at the Almazov National Medical Research Center in the field of clinical genetics and pediatrics. Deoxyribonucleic acid (DNA) isolated from whole blood samples and dried blood spots was used for genetic testing using modern molecular genetic diagnostic methods. Results . The potential of using bioresource collections of pediatric patient biomaterial was demonstrated using familial cases of rare monogenic diseases, for which previously collected biomaterial from the biobank was used to establish a diagnosis and determine follow-up strategies for family members, identify risks to future offspring, and receive advance data on the management of patients with specific hereditary syndromes. Additionally, the ability to predict new phenotypes associated with a known gene, and conversely, to uncover the relationship of new genes with a known phenotype, was demonstrated using examples of familial diseases, where biobank biomaterial enabled segregation analysis. Using biomaterial from cohorts of patients with a specific pathology, the potential for developing novel diagnostic algorithms and laboratory test systems, a differentiated approach to selecting a targeted genetic panel for diagnosis, and the identification of new clinical and genetic disease features was showed. A founder mutation was showed to be identified in a pathology determined in a specific ethnic group, with the potential to describe the onset time and geographic distribution. Conclusion . The creation of bioresource collections obtained from pediatric populations is a complex, yet extremely important, clinically necessary, and promising scientific task. Its implementation facilitates translational research aimed at improving diagnostic methods, understanding the pathogenesis and progression of childhood diseases, and the influence of environmental factors on their development. It also facilitates the search for new genetic causes of hereditary pathologies and the description of new phenotypes associated with known genes. It also identifies predictors of disease severity and prognosis. In the long term, it facilitates the search for novel therapeutic approaches and understanding the disease pathogenesis in adults.
- 23 January 2026
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 24 (11) , 4567
Open AccessPotential and prospects for using biomedical resource collections obtained from pediatric patients for clinics and research
Aim . To demonstrate the development and potential applications of biomedical resource collections of pediatric patient biomaterials, as well as the potential for their differentiated use for clinical and research purposes in a multidisciplinary hospital setting at a federal research center. Material and methods . The study included biomaterial from pediatric patients and their first-degree relatives, banked between 2016 and 2025 as part of research projects at the Almazov National Medical Research Center in the field of clinical genetics and pediatrics. Deoxyribonucleic acid (DNA) isolated from whole blood samples and dried blood spots was used for genetic testing using modern molecular genetic diagnostic methods. Results . The potential of using bioresource collections of pediatric patient biomaterial was demonstrated using familial cases of rare monogenic diseases, for which previously collected biomaterial from the biobank was used to establish a diagnosis and determine follow-up strategies for family members, identify risks to future offspring, and receive advance data on the management of patients with specific hereditary syndromes. Additionally, the ability to predict new phenotypes associated with a known gene, and conversely, to uncover the relationship of new genes with a known phenotype, was demonstrated using examples of familial diseases, where biobank biomaterial enabled segregation analysis. Using biomaterial from cohorts of patients with a specific pathology, the potential for developing novel diagnostic algorithms and laboratory test systems, a differentiated approach to selecting a targeted genetic panel for diagnosis, and the identification of new clinical and genetic disease features was showed. A founder mutation was showed to be identified in a pathology determined in a specific ethnic group, with the potential to describe the onset time and geographic distribution. Conclusion . The creation of bioresource collections obtained from pediatric populations is a complex, yet extremely important, clinically necessary, and promising scientific task. Its implementation facilitates translational research aimed at improving diagnostic methods, understanding the pathogenesis and progression of childhood diseases, and the influence of environmental factors on their development. It also facilitates the search for new genetic causes of hereditary pathologies and the description of new phenotypes associated with known genes. It also identifies predictors of disease severity and prognosis. In the long term, it facilitates the search for novel therapeutic approaches and understanding the disease pathogenesis in adults.
- Open Access
- 25 December 2025
- Published by Publishing House ABV Press in Supportive Therapy in Oncology
- Vol. 2 (3) , 76-84
Cardiovascular toxicity of antiGD2-specific monoclonal antibodies in a patient with osteosarcoma. A clinical case report
Immunotherapy is one of the most effective methods of cancer therapy. There are five main groups of immunotherapy, including treatment with chimeric antigen receptor T cells, checkpoint inhibitors, anticancer vaccines, antibody-based targeted therapies, and oncolytic viruses. On the adult cohort of patients, immunotherapy has been proven to increase the survival rate of patients with cancer. At the same time, in some patients, it can cause an immune-mediated damage and contribute to unfavorable heart immune modulation and heart failure. Immunotherapy can target many components of the cardiovascular system, including the myocardium, blood vessels, electrical wiring, and the pericardium. Activated T lymphocytes (CD4 + and CD8 + T cells) penetrate the heart tissue and skeletal targets, which leads to local inflammation and damage. Additional theoretical mechanisms for side effects include autoantibody recognition of self-antigens and T cell-mediated damage to cardiomyocytes and stressed endothelial cells. After treatment with T cells, the level of proinflammatory cytokines may increase, which is often the cause of cytokine release syndrome, the occurrence of which is considered a “targeted, non-neoplastic” effect. Proinflammatory cytokines can have negative cytotoxic effects on cardiomyocytes, resulting in reduced myocardial contractility, cardiomyopathy, and hypotension. This review presents a clinical case of cardiotoxicity due to the use of antiGD2 monoclonal antibodies in a child with a refractory form of osteosarcoma.
- 25 December 2025
- Published by Publishing House ABV Press in Supportive Therapy in Oncology
- Vol. 2 (3) , 76-84
Open AccessCardiovascular toxicity of antiGD2-specific monoclonal antibodies in a patient with osteosarcoma. A clinical case report
Immunotherapy is one of the most effective methods of cancer therapy. There are five main groups of immunotherapy, including treatment with chimeric antigen receptor T cells, checkpoint inhibitors, anticancer vaccines, antibody-based targeted therapies, and oncolytic viruses. On the adult cohort of patients, immunotherapy has been proven to increase the survival rate of patients with cancer. At the same time, in some patients, it can cause an immune-mediated damage and contribute to unfavorable heart immune modulation and heart failure. Immunotherapy can target many components of the cardiovascular system, including the myocardium, blood vessels, electrical wiring, and the pericardium. Activated T lymphocytes (CD4 + and CD8 + T cells) penetrate the heart tissue and skeletal targets, which leads to local inflammation and damage. Additional theoretical mechanisms for side effects include autoantibody recognition of self-antigens and T cell-mediated damage to cardiomyocytes and stressed endothelial cells. After treatment with T cells, the level of proinflammatory cytokines may increase, which is often the cause of cytokine release syndrome, the occurrence of which is considered a “targeted, non-neoplastic” effect. Proinflammatory cytokines can have negative cytotoxic effects on cardiomyocytes, resulting in reduced myocardial contractility, cardiomyopathy, and hypotension. This review presents a clinical case of cardiotoxicity due to the use of antiGD2 monoclonal antibodies in a child with a refractory form of osteosarcoma.
- Open Access
- 20 June 2024
- Published by Arterialnaya Gipertenziya in Translational Medicine
- Vol. 11 (2) , 201-215
Multisystem involvement and early onset of Danon’s disease in female children. Clinical cases
Danon’s disease (DD) is a rare multisystem disease caused by pathogenic variants in the LAMP2 gene. Men are characterized by a multisystemic Involvement, most often represented by a triad of symptoms: skeletal myopathy, cardiomyopathy (hypertrophic phenotype), and cognitive dysfunction. Women are more likely to have isolated heart disease. Given that women are less likely to have extracardiac manifestations, the diagnosis of the disease in females can be very difficult and untimely. In this article, we present 2 clinical cases of BD in adolescent girls, characterized by an early onset of the disease and a multisystem course.
- 20 June 2024
- Published by Arterialnaya Gipertenziya in Translational Medicine
- Vol. 11 (2) , 201-215
Open AccessMultisystem involvement and early onset of Danon’s disease in female children. Clinical cases
Danon’s disease (DD) is a rare multisystem disease caused by pathogenic variants in the LAMP2 gene. Men are characterized by a multisystemic Involvement, most often represented by a triad of symptoms: skeletal myopathy, cardiomyopathy (hypertrophic phenotype), and cognitive dysfunction. Women are more likely to have isolated heart disease. Given that women are less likely to have extracardiac manifestations, the diagnosis of the disease in females can be very difficult and untimely. In this article, we present 2 clinical cases of BD in adolescent girls, characterized by an early onset of the disease and a multisystem course.
- Open Access
- 20 June 2024
- Published by Arterialnaya Gipertenziya in Translational Medicine
- Vol. 11 (2) , 148-156
Physical performance and physical activity of children with corrected congenital heart defects
Background: despite the great contribution of physical activity (PA) to the health of children after correction of congenital heart defects (CHD), in the literature there are only isolated data on PA and the performance of children after correction of congenital heart defects. Objective: to assess physical activity and physical performance in children after radical intervention for congenital heart disease. Material and methods. The study included 32 children after radical correction of congenital heart disease. In addition to standard research methods, all patients underwent a cardiopulmonary stress test (CPST), as well as a structured interview on physical activity. Results. According to the survey, 81 % of children did not achieve the recommended 60 minutes of daily PA. Only 44 % of children attended sports clubs or sections. The amount of sedentary time in children was 8.4 hours a day, while the duration of entertainment “screen time” was 3 hours. A separate analysis of physical performance was carried out in subgroups formed depending on physical training (PT) activities. In children who regularly engaged in PT, the threshold load power and heart rate at the height of physical activity were higher compared to children who did not engage in PT. In addition, they had higher VO2peak and lower ventilator CO2 equivalent (VE/VCO2). Conclusion. Children with corrected congenital heart disease, without contraindications to physical education and sports, mostly lead a sedentary lifestyle and have insufficient physical activity and performance. However, regular physical training after radical correction of congenital heart disease significantly increases the performance of children due to an adequate increase in cardiac output and minute ventilation during physical activity.
- 20 June 2024
- Published by Arterialnaya Gipertenziya in Translational Medicine
- Vol. 11 (2) , 148-156
Open AccessPhysical performance and physical activity of children with corrected congenital heart defects
Background: despite the great contribution of physical activity (PA) to the health of children after correction of congenital heart defects (CHD), in the literature there are only isolated data on PA and the performance of children after correction of congenital heart defects. Objective: to assess physical activity and physical performance in children after radical intervention for congenital heart disease. Material and methods. The study included 32 children after radical correction of congenital heart disease. In addition to standard research methods, all patients underwent a cardiopulmonary stress test (CPST), as well as a structured interview on physical activity. Results. According to the survey, 81 % of children did not achieve the recommended 60 minutes of daily PA. Only 44 % of children attended sports clubs or sections. The amount of sedentary time in children was 8.4 hours a day, while the duration of entertainment “screen time” was 3 hours. A separate analysis of physical performance was carried out in subgroups formed depending on physical training (PT) activities. In children who regularly engaged in PT, the threshold load power and heart rate at the height of physical activity were higher compared to children who did not engage in PT. In addition, they had higher VO2peak and lower ventilator CO2 equivalent (VE/VCO2). Conclusion. Children with corrected congenital heart disease, without contraindications to physical education and sports, mostly lead a sedentary lifestyle and have insufficient physical activity and performance. However, regular physical training after radical correction of congenital heart disease significantly increases the performance of children due to an adequate increase in cardiac output and minute ventilation during physical activity.
- Open Access
- 27 June 2023
- Published by Institute of Cardio Technics - INCART in Journal of Arrhythmology
- Vol. 30 (2) , 6-11
Clinical characteristics of the “hot phase” of arrhythmogenic cardiomyopathy in a pediatric patient
This article describes a rare clinical manifestation of arrhythmogenic cardiomyopathy in a 13-year-old boy - the “hot phase”, characterized by severe chest pain and a significant increase on a level of troponin I. The clinical case demonstrates the difficulties of the differential diagnosis of this disease and an importance of an integrated approach to examination of the patient, including cardiac magnetic resonance imaging and genetic testing.
- 27 June 2023
- Published by Institute of Cardio Technics - INCART in Journal of Arrhythmology
- Vol. 30 (2) , 6-11
Open AccessClinical characteristics of the “hot phase” of arrhythmogenic cardiomyopathy in a pediatric patient
This article describes a rare clinical manifestation of arrhythmogenic cardiomyopathy in a 13-year-old boy - the “hot phase”, characterized by severe chest pain and a significant increase on a level of troponin I. The clinical case demonstrates the difficulties of the differential diagnosis of this disease and an importance of an integrated approach to examination of the patient, including cardiac magnetic resonance imaging and genetic testing.
- Open Access
- 21 July 2020
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 25 (10) , 4027
Left ventricular noncompaction associated with titin-truncating variants in the TTN gene
Aim. To study the association of genetic variants in the titin gene ( TTN ) with the development and clinical course of left ventricular noncompaction in different age groups. Material and methods. The article discusses three clinical cases of patients with left ventricular noncompaction who were treated at theAlmazovNationalMedicalResearchCenter. We performed a new-generation sequencing of 108 genes associated with cardiomyopathies, as well as whole exome sequencing and Sanger sequencing. Results. We identified genetic variants in the TTN gene leading to the synthesis of truncated protein: in the first two cases, the cause of noncompaction was a thirteen nucleotide deletion with a reading frame shift, in the second, a nonsense mutation. An algorithm for assessing the pathogenicity of the identified variants and a scheme of diagnostic genetic search are presented. Conclusion. Causal role of TTN -truncating variants in development of cardiomyopathies and, in particular, left ventricular noncompaction, requires a comprehensive clinical, segregation and bioinformatic analysis using international databases and the use of bioinformatics software.
- 21 July 2020
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 25 (10) , 4027
Open AccessLeft ventricular noncompaction associated with titin-truncating variants in the TTN gene
Aim. To study the association of genetic variants in the titin gene ( TTN ) with the development and clinical course of left ventricular noncompaction in different age groups. Material and methods. The article discusses three clinical cases of patients with left ventricular noncompaction who were treated at theAlmazovNationalMedicalResearchCenter. We performed a new-generation sequencing of 108 genes associated with cardiomyopathies, as well as whole exome sequencing and Sanger sequencing. Results. We identified genetic variants in the TTN gene leading to the synthesis of truncated protein: in the first two cases, the cause of noncompaction was a thirteen nucleotide deletion with a reading frame shift, in the second, a nonsense mutation. An algorithm for assessing the pathogenicity of the identified variants and a scheme of diagnostic genetic search are presented. Conclusion. Causal role of TTN -truncating variants in development of cardiomyopathies and, in particular, left ventricular noncompaction, requires a comprehensive clinical, segregation and bioinformatic analysis using international databases and the use of bioinformatics software.
- 15 June 2020
- Published by Pediatria, Ltd. in Pediatria. Journal named after G.N. Speransky
- Vol. 99 (3)
FEATURES OF THE CLINICAL PHENOTYPE OF FILAMINE CARDIOMYOPATHIES WITH A DEBUT IN EARLY CHILDHOOD
Облако Mail.ru - это ваше персональное надежное хранилище в интернете.
- 15 June 2020
- Published by Pediatria, Ltd. in Pediatria. Journal named after G.N. Speransky
- Vol. 99 (3)
FEATURES OF THE CLINICAL PHENOTYPE OF FILAMINE CARDIOMYOPATHIES WITH A DEBUT IN EARLY CHILDHOOD
Облако Mail.ru - это ваше персональное надежное хранилище в интернете.
- Open Access
- 5 January 2020
- Published by Paediatrician Publishers LLC in Current Pediatrics
- Vol. 18 (5) , 346-353
Damages of Cardiovascular System at Mucopolysaccharidosis Type I: Clinical Cases
Поражение сердечно-сосудистой системы при мукополисахаридозе I типа: клинические случаи
- 5 January 2020
- Published by Paediatrician Publishers LLC in Current Pediatrics
- Vol. 18 (5) , 346-353
Open AccessDamages of Cardiovascular System at Mucopolysaccharidosis Type I: Clinical Cases
Поражение сердечно-сосудистой системы при мукополисахаридозе I типа: клинические случаи
- Open Access
- 3 November 2019
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- No. 10,p. 92-99
Variants of RBM20 gene in pediatric patients with dilated cardiomyopathy
Варианты в гене RBM20 у пациентов детского возраста с дилатационной кардиомиопатией
- 3 November 2019
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- No. 10,p. 92-99
Open AccessVariants of RBM20 gene in pediatric patients with dilated cardiomyopathy
Варианты в гене RBM20 у пациентов детского возраста с дилатационной кардиомиопатией
- Open Access
- 10 April 2018
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- No. 3,p. 54-59
BARTH SYNDROME IN PRACTICE OF CARDIOLOGY
СИНДРОМ БАРТА В ПРАКТИКЕ КАРДИОЛОГА
- 10 April 2018
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- No. 3,p. 54-59
Open AccessBARTH SYNDROME IN PRACTICE OF CARDIOLOGY
СИНДРОМ БАРТА В ПРАКТИКЕ КАРДИОЛОГА